Close Menu

NEW YORK ─  Shares of several in vitro diagnostic companies plummeted on Monday following an announcement that a vaccine developed by Pfizer and BioNTech demonstrated 90 percent efficacy in a clinical study at protecting people from COVID-19.

Shares of Quidel, Fulgent Genetics, Fluidigm, Meridian Bioscience, and GenMark Diagnostics were among those that slid sharply after the vaccine announcement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.